Who are Hydroxychloroquine in combination of Azithromycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hydroxychloroquine combined with Azithromycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroxychloroquine-in-combination-of-azithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Hydroxychloroquine in combination of Azithromycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hydroxychloroquine in combination of Azithromycin (Hydroxychloroquine in combination of Azithromycin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial + Macrolide antibiotic combination. Area: Infectious Disease / Immunology.

phase 3 Antimalarial + Macrolide antibiotic combination Infectious Disease / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Hydroxychloroquine in combination of Azithromycin (Hydroxychloroquine in combination of Azithromycin) — Sheba Medical Center. Hydroxychloroquine inhibits viral entry and endosomal acidification while azithromycin provides antimicrobial and immunomodulatory effects, together targeting viral replication and inflammatory response.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydroxychloroquine in combination of Azithromycin TARGET	Hydroxychloroquine in combination of Azithromycin	Sheba Medical Center	phase 3	Antimalarial + Macrolide antibiotic combination
Hydroxychloroquine combined with Azithromycin	Hydroxychloroquine combined with Azithromycin	Ministry of Health, Turkey	phase 3	Antimalarial + Macrolide antibiotic combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial + Macrolide antibiotic combination class)

Ministry of Health, Turkey · 1 drug in this class
Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxychloroquine in combination of Azithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxychloroquine-in-combination-of-azithromycin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab